EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Expert Q&A

What should buyers establish before discussing price?

Dose Diligence research deskSection 06 · Page 1 of 22Last updated 17 Nov 2026

Start with the exact product, facility, patient destination and transaction—not a supplier category. FDA distinguishes compounded preparations from approved drugs and explains that the oversight and quality requirements differ between qualifying 503A compounding and 503B outsourcing. A compounder’s registration or a pharmacy relationship should therefore not be treated as product approval. (fda.gov)

Use the interviews in this order:

Decision gateQuestionsRequired output
What arrangement are we evaluating?1Product, responsibility and money-flow map
Is the proposed route supportable?2–4Product-specific legal assessment and destination-state evidence
Can we assess quality and provenance?5–7Facility evidence register, handling controls and traceability responsibilities
Does access work economically and operationally?8–11Workflow comparison, matched quotations and measurable service commitments
Can we withstand disruption and leave safely?12–16Tested fallback, clinical transition plan and reviewed contracts

Recommended procurement rule: Keep unresolved route-eligibility and critical quality questions outside price-weighted rankings. Record them as approval gates rather than allowing a low quotation to offset missing evidence.

Explore the table row by row

A working view of the research

What arrangement are we evaluating?

Questions
1
Required output
Product, responsibility and money-flow map

Sources cited on this page

  1. fda.gov · Source 1 ↗https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
Section sources →